Phibro Animal Health Corporation Class A (PAHC)

Over the past six months, Phibro Animal Health Corp.'s stock price has seen significant movement, with a rise of 35.51%. Key events impacting the stock include strong earnings reports and guidance, the Zoetis Medicated Feed Additive (MFA) Acquisition, credit facility expansion, regulatory headwinds in Brazil, and analyst ratings. The company reported strong fiscal Q2 2026 earnings, beating EPS expectations, and a robust Q3 fiscal 2026 with net sales increasing 10% to $383.5 million and adjusted EBITDA rising 11% to $60.8 million. The acquisition of the Zoetis MFA portfolio in October 2024 has been a significant growth driver. In late April, Phibro announced an expansion of its revolving credit facility from $310 million to $435 million. A regulatory development in Brazil affecting certain antimicrobial products was announced after the Q3 fiscal 2026 quarter end, contributing to a sharp stock decline. As of May 7, 2026, analysts have an average "Hold" rating on PAHC stock, with a mean 12-month target price of $42.40.

The provided information does not explicitly detail the demand seasonality for Phibro Animal Health Corp.'s products and services. However, the company's business is concentrated in the livestock sector, which could imply some seasonality related to agricultural cycles, breeding seasons, or disease outbreaks. The company has focused its efforts in regions where the majority of livestock production is consolidated in large commercial farms.

Phibro Animal Health Corporation (PAHC) is a global animal health and mineral nutrition company headquartered in Teaneck, New Jersey, and publicly listed on the NASDAQ since 2014. The company operates in the healthcare sector, specifically in the drug manufacturers industry. Phibro develops, manufactures, and markets a range of product lines for food and companion animals. Its operations are divided into three main segments: Animal Health, which focuses on medicated feed additives, nutritional specialty products, and vaccines; Mineral Nutrition, which provides trace minerals for animal diets; and Performance Products, which manufactures specialty ingredients for various industries.

Phibro Animal Health Corp. has a significant global presence, operating in over 80 to 95 countries and serving approximately 4,000 to 4,500 customers. The company's operations span the United States, Latin America, Canada, Europe, the Middle East, Africa, and Asia-Pacific. Phibro has manufacturing sites in the U.S., Italy, and China, and established a biotech facility in Sligo, Ireland, in 2018.

Phibro Animal Health Corporation strives to be a trusted partner with livestock producers, farmers, veterinarians, and consumers. The company launched its Sustainable Solutions Platform, including VERRATAIN™ Verified Sustainability Solutions, through a strategic partnership with VAXA Technologies. Phibro highlights its unique, scientifically proven products and a strong focus on prevention over cure. Recent regulatory developments in Brazil concerning antimicrobial products could potentially impact the company's reputation in that market.

Phibro Animal Health Corporation's ownership structure includes public shareholders, institutional investors, and significant insider holdings. The Bendheim family, through BFI Co., LLC, is the majority owner of the company's voting power. Major institutional investors hold a substantial number of shares. Insiders hold 62.78% of Phibro Animal Health stock, and there have been reports of insider selling.